Celldex Therapeutics , Inc. (NASDAQ:CLDX), a biopharmaceutical company focused on developing innovative therapies for ...

Celldex Therapeutics , Inc. (NASDAQ:CLDX), with a market capitalization of $1.72 billion, is a biopharmaceutical company focused on developing innovative therapies for challenging diseases, with its ...

A year after reducing half of its workforce, Allakos will downsize to just 15 employees as it halts the development of AK006.

California, USA-based biotech Allakos saw its shares plummet 78.8% to $0.26 yesterday, after it announced disappointing ...

Allakos, Bay Area biotech firm based in San Carlos, is laying off 75% of its staff and eyeing a shutdown after its clinical ...

It was the best of biotech times, it was the worst of biotech times: One company soars, another stumbles and a third outlines ...

Allakos halts AK006 development after phase 1 trial disappoints. Restructuring includes workforce cuts and $34 million-$38 ...

Following disappointing clinical trial results for AK006, Allakos will cut its workforce down to under 20 employees as it ...

Allakos said it plans to explore strategic alternatives, adding that it expects its cash, equivalents and investments will total $35 million to $40 million by the end of June. The company now sports a ...

JMP Securities downgraded Allakos (ALLK) to Market Perform from Outperform without a price target after the company’s Phase 1 clinical trial of ...

Allakos is throwing in the towel. After seeing phase 1 data in hives, the biotech has decided to drop the drug candidate and ...

The San Carlos, Calif., clinical-stage biotechnology company, which ended 2024 with roughly $81 million in cash, equivalents and investments, said it expects to use $34 million to $38 million in cash ...